Source-grounded facts extracted from KEWAUNEE SCIENTIFIC CORP /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KEWAUNEE SCIENTIFIC CORP /DE/ reported third quarter ended January 31, 2026 results: revenue $69,399,000, net income $692,000, EPS $0.23.
“Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA 1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter.”
Material Agreements
KEWAUNEE SCIENTIFIC CORP /DE/ terminated Seller Notes with Richard A. Peters, William F. Peters, Rita Peters Revocable Trust, Richard A. Peters Revocable Trust, Karan A. Peters Revocable Trust, William F. Peters 2023 Irrevocable Trust dated December 20, 2023, William F. Peters Revocable Trust valued at $23.0 million (effective 2025-12-04).
“The First Amendment amends the Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement"), between the Company and PNC to, among other things, (i) permit the Company to repay in full the outstanding principal balances of the subordinated seller notes issued by the Company in connection with its acquisition of Nu Aire, Inc.”
Material Agreements
KEWAUNEE SCIENTIFIC CORP /DE/ amended First Amendment to Loan Agreement with PNC Bank, National Association (effective 2025-12-04).
“On December 4, 2025, Kewaunee Scientific Corporation (the "Company") entered into a First Amendment to Loan Agreement (the "First Amendment") with PNC Bank, National Association ("PNC").”
Governance Changes
KEWAUNEE SCIENTIFIC CORP /DE/: Amended Bylaws to change the range of authorized board size to at least five and not more than nine directors, with exact number fixed by board resolution (effective 2025-09-10).
“Effective September 10, 2025, the Board approved Amended and Restated Bylaws (the "Bylaws"), which reflect an amendment to Section 5.02 to provide that the number of directors constituting the whole Board will be at least five and not more than nine directors, the exact number to be fixed from time to time by resolution of the Board adopted by the directors then in office.”
M&A Transactions
KEWAUNEE SCIENTIFIC CORP /DE/ completed an acquisition involving Nu Aire, Inc. for $55,000,000 (closed 2024-11-01).
“(after the RWI Policy is exhausted). Pursuant to the terms of the Purchase Agreement, the Company purchased all of the outstanding capital stock of Nu Aire from the Sellers for $55,000,000 in the aggregate (the “Purchase Price”), subject to certain customary adjustments for debt, cash, transaction expenses and net working capital, as further described in the”
Earnings Releases
KEWAUNEE SCIENTIFIC CORP /DE/ reported third quarter ended January 31, 2024 results: revenue $46,778,000, net income $2,521,000, EPS $0.85.
“Sales during the third quarter of fiscal year 2024 were $46,778,000, a decrease of 23.1% compared to sales of $60,821,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $3,515,000 compared to $2,060,000 for the prior year quarter, an increase of 70.6%. Net earnings were $2,521,000 compared to net earnings of $723,000 for the prior year quarter. EBITDA 1 for the quarter was $4,414,000 compared to $2,683,000 for the prior year quarter. Diluted earnings per share was $0.85 compared to diluted earnings per share of $0.25 in the prior year quarter.”
Earnings Releases
KEWAUNEE SCIENTIFIC CORP /DE/ reported second quarter ended October 31, 2023 results: revenue $50,436,000, net income $2,732,000, EPS $0.93.
“KEQU) today announced results for its second quarter ended October 31, 2023. Fiscal Year 2024 Second Quarter Results: Sales during the second quarter of fiscal year 2024 were $50,436,000, a decrease of 7.6% compared to sales of $54,564,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $4,845,000 compared to $456,000 for the prior year”
Earnings Releases
KEWAUNEE SCIENTIFIC CORP /DE/ reported financial results for first quarter of fiscal year 2024.
“On August 31, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2024.”
Shareholder Votes
KEWAUNEE SCIENTIFIC CORP /DE/ shareholders approved Approval of Kewaunee Scientific Corporation 2023 Omnibus Incentive Plan at the 2023-08-23 meeting.
“4. The Kewaunee Scientific Corporation 2023 Omnibus Incentive Plan, as amended, was approved as follows: For Against Abstained Non-Votes 1,419,893 498,027 1,613 560,185”
Shareholder Votes
KEWAUNEE SCIENTIFIC CORP /DE/ shareholders approved Advisory vote on executive compensation at the 2023-08-23 meeting.
“3. The compensation of the Company’s named executive officers was approved on an advisory basis as follows: For Against Abstained Non-Votes 1,839,983 65,792 13,758 560,185”
Shareholder Votes
KEWAUNEE SCIENTIFIC CORP /DE/ shareholders approved Ratification of appointment of FORVIS, LLP as independent auditors at the 2023-08-23 meeting.
“2. The appointment of the independent registered public accounting firm of FORVIS, LLP as the Company’s independent auditors for fiscal year 2024 was ratified as follows: For Against Abstained 2,476,494 57 3,167”
Earnings Releases
KEWAUNEE SCIENTIFIC CORP /DE/ reported financial results for the fourth quarter and fiscal year ended April 30, 2023.
“On June 28, 2023, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and fiscal year ended April 30, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.